Mustang Bio (MBIO) Competitors $1.11 +0.02 (+1.83%) Closing price 05/1/2025 03:57 PM EasternExtended Trading$1.11 0.00 (0.00%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. PRPH, INAB, IPA, TXMD, GOVX, MBRX, TRIB, CLDI, CLRB, and ABPShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include ProPhase Labs (PRPH), IN8bio (INAB), ImmunoPrecise Antibodies (IPA), TherapeuticsMD (TXMD), GeoVax Labs (GOVX), Moleculin Biotech (MBRX), Trinity Biotech (TRIB), Calidi Biotherapeutics (CLDI), Cellectar Biosciences (CLRB), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. ProPhase Labs IN8bio ImmunoPrecise Antibodies TherapeuticsMD GeoVax Labs Moleculin Biotech Trinity Biotech Calidi Biotherapeutics Cellectar Biosciences Abpro Mustang Bio (NASDAQ:MBIO) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Is MBIO or PRPH more profitable? Mustang Bio has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. Mustang Bio's return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Mustang BioN/A N/A -172.89% ProPhase Labs -217.64%-62.92%-30.22% Do analysts prefer MBIO or PRPH? Mustang Bio currently has a consensus price target of $100.00, indicating a potential upside of 8,909.01%. Given Mustang Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Mustang Bio is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, MBIO or PRPH? Mustang Bio has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500. Does the MarketBeat Community believe in MBIO or PRPH? Mustang Bio received 55 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformMustang BioOutperform Votes16964.26% Underperform Votes9435.74% ProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% Does the media refer more to MBIO or PRPH? In the previous week, Mustang Bio and Mustang Bio both had 1 articles in the media. ProPhase Labs' average media sentiment score of 1.89 beat Mustang Bio's score of 0.94 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Overall Sentiment Mustang Bio Positive ProPhase Labs Very Positive Do institutionals and insiders hold more shares of MBIO or PRPH? 9.9% of Mustang Bio shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.2% of Mustang Bio shares are held by company insiders. Comparatively, 20.7% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, MBIO or PRPH? ProPhase Labs has higher revenue and earnings than Mustang Bio. ProPhase Labs is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMustang BioN/AN/A-$51.60M-$78.00-0.01ProPhase Labs$6.77M2.00-$16.78M-$1.26-0.26 SummaryMustang Bio beats ProPhase Labs on 10 of the 16 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.67M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-0.017.3222.5318.54Price / SalesN/A241.43399.57103.29Price / CashN/A65.8538.1834.62Price / Book1.666.486.774.25Net Income-$51.60M$143.41M$3.22B$248.18M7 Day Performance-9.02%1.91%1.11%0.91%1 Month Performance-22.92%4.28%2.50%2.58%1 Year Performance-92.42%-3.87%15.76%4.02% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio2.6088 of 5 stars$1.11+1.8%$100.00+8,909.0%-91.7%$3.67MN/A-0.01100News CoveragePRPHProPhase Labs1.0337 of 5 stars$0.35-5.0%N/A-93.8%$14.67M$6.77M-0.28130Upcoming EarningsPositive NewsGap DownINABIN8bio3.6065 of 5 stars$0.18-6.0%$6.00+3,270.8%-83.7%$14.46MN/A-0.2420Upcoming EarningsPositive NewsIPAImmunoPrecise Antibodies2.7828 of 5 stars$0.46+2.4%$4.00+768.4%-62.7%$14.31M$24.00M-0.5980Short Interest ↓Gap UpTXMDTherapeuticsMD1.766 of 5 stars$1.22+6.1%N/A-26.1%$14.12M$1.76M0.00420Upcoming EarningsAnalyst ForecastGOVXGeoVax Labs2.7825 of 5 stars$1.02+4.4%$12.90+1,164.7%-33.2%$14.12M$3.95M-0.1810Earnings ReportNews CoverageMBRXMoleculin Biotech2.9459 of 5 stars$0.99-6.9%$6.00+508.1%-79.6%$13.81MN/A0.0020Upcoming EarningsShort Interest ↓TRIBTrinity Biotech1.6652 of 5 stars$0.76+7.3%N/A-54.6%$13.72M$59.13M-0.34480Analyst ForecastShort Interest ↓Positive NewsGap UpCLDICalidi Biotherapeutics2.002 of 5 stars$0.48-0.3%$15.00+3,014.0%N/A$13.71M$50,000.000.0038CLRBCellectar Biosciences1.7425 of 5 stars$0.30-4.4%$12.50+4,117.3%-91.6%$13.66MN/A-0.1710Gap UpABPAbproN/A$0.26-18.0%$4.00+1,434.3%N/A$13.61M$183,000.000.0015Gap UpHigh Trading Volume Related Companies and Tools Related Companies PRPH Alternatives INAB Alternatives IPA Alternatives TXMD Alternatives GOVX Alternatives MBRX Alternatives TRIB Alternatives CLDI Alternatives CLRB Alternatives ABP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBIO Stock Free MBIO Stock Alerts